Enterprise Value
13.07M
Cash
44.29M
Avg Qtr Burn
N/A
Short % of Float
2.26%
Insider Ownership
37.46%
Institutional Own.
12.90%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EVOMELA (melphalan) Details MM (Multiple Myeloma) | Approved Quarterly sales | |
CNCT19 (Anti-CD19) Details Non-Hodgkin lymphoma | Phase 2 Data readout | |
BI-1206 (Anti-FcyRIIB antibody) Details Solid tumor/s, Non-Hodgkin lymphoma, Blood cancer, Cancer | Phase 1/2 Update |